High dosage strength tablets of rucaparib
View Patent ↗A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.
1. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a tablet comprising 45-90% w/w of an active pharmaceutical ingredient compound 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate.
2. The method according to claim 1 , wherein the active pharmaceutical ingredient is included in the range of 50-90%.
3. The method according to claim 1 , wherein the active pharmaceutical ingredient is included in the range of 55-90%.
4. The method according to claim 1 , wherein the active pharmaceutical ingredient is included in the range of 60-90%.
5. The method according to claim 1 , wherein the active pharmaceutical ingredient is included in the range of 65-85%.
6. The method according to claim 1 , wherein the active pharmaceutical ingredient is included in the range of 70-80%.
7. The method according to claim 1 , wherein the tablet includes 200 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.
8. The method according to claim 1 , wherein the tablet includes 250 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.
9. The method according to claim 1 , wherein the tablet includes 300 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.
10. The method according to claim 1 , wherein the mammal is a human being.
11. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a dry granulated tablet comprising 45-90% w/w of an active pharmaceutical ingredient compound 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate, wherein the tablet includes 200 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.